Eperezolid

Drug Profile

Eperezolid

Alternative Names: PNU 100592; U 100592

Latest Information Update: 18 Sep 2001

Price : $50

At a glance

  • Originator Pharmacia Corporation
  • Class Acetamides; Antibacterials; Oxazolidinones; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Gram-positive infections

Most Recent Events

  • 18 Sep 2001 Discontinued-III for Gram-positive infections in USA (Unknown route)
  • 05 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
  • 09 Sep 1999 An in vitro study has been added to the Bacterial Infections antimicrobial activity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top